Form 4: Bicara CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Bicara Therapeutics CFO Ivan Hyep executed planned sales of common stock and option exercises on March 3 and 4, 2026, under a Rule 10b5-1 trading plan.

Summary

• Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc. (BCAX), reported transactions involving the company's common stock.
• On March 3, 2026, Mr. Hyep acquired 7,318 shares and 6,237 shares of common stock through option exercises at an exercise price of $3.7898 per share.
• On the same day, he disposed of 13,555 shares of common stock at a weighted average price of $18.2154 per share, with prices ranging from $18.15 to $18.31.
• On March 4, 2026, Mr. Hyep acquired 2,963 shares of common stock through option exercise at an exercise price of $3.7898 per share.
• Also on March 4, 2026, he disposed of 2,963 shares of common stock at a weighted average price of $18.2456 per share, with prices ranging from $18.15 to $18.44.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
• Following these transactions, Mr. Hyep beneficially owns 145,355 shares of common stock directly.
• Remaining derivative securities include stock options to buy 58,144 shares (vesting from April 5, 2023, expiring April 5, 2033) and 79,784 shares (vesting from August 8, 2023, expiring August 8, 2033).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event as the transactions were pre-scheduled under a 10b5-1 plan, indicating a planned liquidity event rather than a reaction to new information.

Positives

• The Chief Financial Officer exercised stock options, indicating a realization of value from previously granted equity awards.
• Shares were sold at a significantly higher price ($18.2154 and $18.2456) than the exercise price ($3.7898), demonstrating a substantial gain for the officer.

Negatives

• The Chief Financial Officer sold a total of 16,518 shares of common stock, which could be interpreted by some investors as a reduction in insider exposure.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance, as it is a report of past insider transactions.

Industry Context

StockSavvy.ai notes that insider sales, even when executed under a Rule 10b5-1 plan, are routinely monitored by investors for potential insights into management's view of future stock performance. However, the pre-scheduled nature of these transactions typically reduces their perceived signaling value compared to unscheduled sales.

Stakeholder Impact

• Shareholders may observe the CFO's sale of shares, but the pre-arranged nature under a 10b5-1 plan generally mitigates concerns about a lack of confidence in the company's future prospects.

Next Steps

• Continued vesting of remaining stock options for the reporting person, subject to continued service.

Key Dates

Recommendation

The transactions represent pre-planned sales and option exercises by a corporate officer under a Rule 10b5-1 plan, which typically indicates a scheduled liquidity event rather than a reaction to new material information. While insider sales can sometimes be a negative signal, the pre-arranged nature of these transactions suggests a neutral impact on the company's fundamental outlook, warranting a 'hold' recommendation.

Keywords

Bicara Therapeutics, BCAX, Form 4, Insider Trading, Stock Sale, Option Exercise, CFO, Ivan Hyep, 10b5-1 Plan